\-\ Texto\\:\\ \ \(0\)\
\-\ initial\\ labs\\:\ \(0\)\
\-\ hemoglobin\\ 10\\.3\\ m\\/ul\ \(0\)\
\-\ hematocrit\\ 29\\.2\\ \\%\ \(0\)\
\-\ normal\\ reticulocyte\\ counts\\,\\ iron\\,\\ tibc\\ and\\ iron\\ saturation\\.\ \(0\)\
\-\ labs\\ after\\ ct\\ of\\ the\\ abdomen\\ and\\ pelvis\\:\ \(0\)\
\-\ ca\\ 125\\:\\ \\ 1365\\ \\(0\\-34\\ u\\/ml\\)\ \(0\)\
\-\ patient\\ in\\ pending\\ evaluation\\ by\\ gynecology\\ oncology\\.\ \(0\)\
\-\ contrast\\ enhanced\\ axial\\ images\\ of\\ the\\ abdomen\\ and\\ pelvis\\ demonstrate\\ a\\ soft\\ tissue\\ density\\ in\\ lower\\ abdomen\\ between\\ the\\ abdominal\\ wall\\ and\\ small\\ bowel\\ consistent\\ with\\ an\\ omental\\ cake\\.\\ \\ \ \(0\)\
\-\ a\\ fluid\\ collection\\ in\\ the\\ pelvis\\ with\\ a\\ cystic\\ lesion\\ in\\ the\\ left\\ ovary\\ is\\ demonstrated\\.\ \(0\)\
\-\ ovarian\\ cancer\ \(16\)\
\-\ ovarian\\ cancer\\ with\\ peritoneal\\ carcinomatosis\ \(0\)\
\-\ metastatic\\ disease\\ from\\ occult\\ colon\\ or\\ stomach\\ cancer\ \(0\)\
\-\ 74\\ year\\ old\\ white\\ female\\ with\\ normocytic\\,\\ normochromic\\ anemia\\.\\ \\ evaluation\\ for\\ lymphoma\\.\ \(0\)\
\-\ the\\ ct\\ of\\ the\\ abdomen\\ and\\ pelvis\\ in\\ this\\ case\\ carried\\ the\\ provisional\\ diagnosis\\ of\\ lymphoma\\.\\ \\ the\\ patient\\'s\\ examination\\ did\\ not\\ demonstrate\\ evidence\\ of\\ lymphadenopathy\\.\\ \\ \ \(0\)\
\-\ omental\\ cake\\ represents\\ soft\\ tissue\\ attenuation\\ that\\ can\\ occur\\ within\\ the\\ peritoneum\\ from\\ metastatic\\ disease\\ from\\ ovarian\\,\\ gastric\\ or\\ colon\\ malignancy\\.\\ \\ with\\ the\\ constellation\\ of\\ peritoneal\\ fluid\\ and\\ a\\ cystic\\ appearance\\ to\\ the\\ left\\ ovary\\,\\ ovarian\\ cancer\\ was\\ the\\ most\\ likely\\ diagnosis\\.\\ \\ subsequent\\ ultrasound\\ of\\ the\\ abdomen\\ demonstrated\\ a\\ complex\\ fluid\\ collection\\ within\\ the\\ culdesac\\ but\\ no\\ identifiable\\ cysts\\ or\\ additional\\ information\\.\\ \\ \ \(0\)\
\-\ ca\\ 125\\ is\\ expressed\\ by\\ coelomic\\ epithelium\\ in\\ fetal\\ development\\ and\\ is\\ most\\ often\\ expressed\\ by\\ epithelial\\ ovarian\\ cancer\\.\\ \\ it\\ can\\,\\ however\\,\\ be\\ expressed\\ in\\ other\\ malignancies\\.\ \(0\)\
\-\ subsequently\\,\\ a\\ ca\\ 125\\ was\\ drawn\\ and\\ was\\ strongly\\ positive\\ and\\ suggestive\\ for\\ ovarian\\ cancer\\.\\ \\ this\\ tumor\\ marker\\ has\\ been\\ used\\ as\\ an\\ adjunct\\ in\\ postmenopausal\\ women\\ with\\ asymptomatic\\ pelvic\\ masses\\.\\ \\ levels\\ greater\\ than\\ 65\\ units\\ per\\ ml\\ have\\ a\\ positive\\ predictive\\ value\\ of\\ 98\\ percent\\ for\\ ovarian\\ cancer\\.\ \(0\)\
\-\ perkins\\,\\ g\\.\\,\\ slater\\,\\ e\\.\\,\\ sanders\\,\\ g\\.\\,\\ and\\ prichard\\,\\ j\\.\\ \\ \\"serum\\ tumor\\ markers\\.\\"\\ \\ american\\ family\\ physician\\.\\ volume\\ 68\\,\\ number\\ 6\\,\\ september\\ 15\\,\\ 2003\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ ovarian\\:\\ 0\\.08074249415544685\ \(0\)\
\-\ expressed\\:\\ 0\\.0596112998432448\ \(0\)\
\-\ cancer\\:\\ 0\\.05800636239101285\ \(0\)\
\-\ 125\\:\\ 0\\.054048391352781305\ \(0\)\
\-\ cake\\:\\ 0\\.045527469824769254\ \(0\)\
\-\ abdomen\\:\\ 0\\.037336051075157764\ \(0\)\
\-\ pelvis\\:\\ 0\\.03663824668544694\ \(0\)\
\-\ ca\\:\\ 0\\.035214482451460354\ \(0\)\
\-\ omental\\:\\ 0\\.03377271959060874\ \(0\)\
\-\ g\\.\\:\\ 0\\.03214290615917418\ \(0\)\
\-\ iron\\:\\ 0\\.031749446722603845\ \(0\)\
\-\ ovary\\:\\ 0\\.027202512121389574\ \(0\)\
\-\ peritoneal\\:\\ 0\\.026230504846604583\ \(0\)\
\-\ m\\/ul\\:\\ 0\\.026004479126744834\ \(0\)\
\-\ 1365\\:\\ 0\\.026004479126744834\ \(0\)\
\-\ normochromic\\:\\ 0\\.026004479126744834\ \(0\)\
\-\ culdesac\\:\\ 0\\.026004479126744834\ \(0\)\
\-\ coelomic\\:\\ 0\\.026004479126744834\ \(0\)\
\-\ perkins\\:\\ 0\\.026004479126744834\ \(0\)\
\-\ prichard\\:\\ 0\\.026004479126744834\ \(0\)\
\-\ 29\\.2\\:\\ 0\\.023959797178190422\ \(0\)\
\-\ reticulocyte\\:\\ 0\\.023959797178190422\ \(0\)\
\-\ 0\\-34\\:\\ 0\\.023959797178190422\ \(0\)\
\-\ slater\\:\\ 0\\.023959797178190422\ \(0\)\
\-\ sanders\\:\\ 0\\.022763734912384627\ \(0\)\
\-\ normocytic\\:\\ 0\\.02191511522963601\ \(0\)\
\-\ fluid\\:\\ 0\\.021492381456671265\ \(0\)\
\-\ collection\\:\\ 0\\.02133935924897152\ \(0\)\
\-\ tibc\\:\\ 0\\.02125687466528731\ \(0\)\
\-\ carried\\:\\ 0\\.020719052963830215\ \(0\)\
\-\ postmenopausal\\:\\ 0\\.020719052963830215\ \(0\)\
\-\ u\\/ml\\:\\ 0\\.0198704332810816\ \(0\)\
\-\ colon\\:\\ 0\\.01979901421724094\ \(0\)\
\-\ provisional\\:\\ 0\\.01952299069802442\ \(0\)\
\-\ 10\\.3\\:\\ 0\\.019212192716732898\ \(0\)\
\-\ gynecology\\:\\ 0\\.019212192716732898\ \(0\)\
\-\ predictive\\:\\ 0\\.018674371015275804\ \(0\)\
\-\ adjunct\\:\\ 0\\.018438256833347967\ \(0\)\
\-\ counts\\:\\ 0\\.018219649245873864\ \(0\)\
\-\ labs\\:\\ 0\\.017533769952419693\ \(0\)\
\-\ ml\\:\\ 0\\.017478308749470012\ \(0\)\
\-\ peritoneum\\:\\ 0\\.017167510768178487\ \(0\)\
\-\ identifiable\\:\\ 0\\.01702358698006807\ \(0\)\
\-\ september\\:\\ 0\\.01688635979530437\ \(0\)\
\-\ markers\\:\\ 0\\.016755233652027576\ \(0\)\
\-\ epithelium\\:\\ 0\\.016509270203829786\ \(0\)\
\-\ marker\\:\\ 0\\.016393574884793555\ \(0\)\
\-\ positive\\:\\ 0\\.016359207022325174\ \(0\)\
\-\ constellation\\:\\ 0\\.016282246483664217\ \(0\)\
\-\ oncology\\:\\ 0\\.01607145307958709\ \(0\)\
\-\ malignancies\\:\\ 0\\.01607145307958709\ \(0\)\
\-\ 98\\:\\ 0\\.015602235691298929\ \(0\)\
\-\ drawn\\:\\ 0\\.01551672673297075\ \(0\)\
\-\ units\\:\\ 0\\.01551672673297075\ \(0\)\
\-\ carcinomatosis\\:\\ 0\\.0154336268009156\ \(0\)\
\-\ hemoglobin\\:\\ 0\\.015352803868207296\ \(0\)\
\-\ epithelial\\:\\ 0\\.015352803868207296\ \(0\)\
\-\ e\\.\\:\\ 0\\.015274136472684698\ \(0\)\
\-\ occult\\:\\ 0\\.015197512618987764\ \(0\)\
\-\ hematocrit\\:\\ 0\\.014841677846749961\ \(0\)\
\-\ saturation\\:\\ 0\\.014841677846749961\ \(0\)\
\-\ demonstrated\\:\\ 0\\.014793038244583879\ \(0\)\
\-\ evaluation\\:\\ 0\\.014644476671544587\ \(0\)\
\-\ cystic\\:\\ 0\\.01454060594248825\ \(0\)\
\-\ lymphoma\\:\\ 0\\.014408251530321449\ \(0\)\
\-\ 74\\:\\ 0\\.014406173425493133\ \(0\)\
\-\ \\,\\:\\ 0\\.014373985779678976\ \(0\)\
\-\ value\\:\\ 0\\.014292703570543883\ \(0\)\
\-\ 68\\:\\ 0\\.014292703570543883\ \(0\)\
\-\ strongly\\:\\ 0\\.014026771131032682\ \(0\)\
\-\ information\\:\\ 0\\.013736387435418366\ \(0\)\
\-\ percent\\:\\ 0\\.013736387435418366\ \(0\)\
\-\ fetal\\:\\ 0\\.012830708865226886\ \(0\)\
\-\ metastatic\\:\\ 0\\.012690910935788143\ \(0\)\
\-\ 2003\\:\\ 0\\.012665869754918754\ \(0\)\
\-\ by\\:\\ 0\\.0125917779048219\ \(0\)\
\-\ number\\:\\ 0\\.012571213959781585\ \(0\)\
\-\ anemia\\:\\ 0\\.012540325169612572\ \(0\)\
\-\ 65\\:\\ 0\\.012304210987684737\ \(0\)\
\-\ soft\\:\\ 0\\.012276854064858702\ \(0\)\
\-\ women\\:\\ 0\\.012248021621989473\ \(0\)\
\-\ serum\\:\\ 0\\.012165694813384528\ \(0\)\
\-\ represents\\:\\ 0\\.012112059653847092\ \(0\)\
\-\ american\\:\\ 0\\.012007629190570053\ \(0\)\
\-\ tissue\\:\\ 0\\.011949387542493178\ \(0\)\
\-\ volume\\:\\ 0\\.01190676970753678\ \(0\)\
\-\ physician\\:\\ 0\\.011882084605263871\ \(0\)\
\-\ tumor\\:\\ 0\\.011753582900358769\ \(0\)\
\-\ most\\:\\ 0\\.011639145378926703\ \(0\)\
\-\ demonstrate\\:\\ 0\\.011601487559486966\ \(0\)\
\-\ diagnosis\\:\\ 0\\.011576515225843185\ \(0\)\
\-\ can\\:\\ 0\\.011434940132560882\ \(0\)\
\-\ subsequently\\:\\ 0\\.011427362835861928\ \(0\)\
\-\ j\\:\\ 0\\.011385520254764712\ \(0\)\
\-\ gastric\\:\\ 0\\.011263439971098476\ \(0\)\
\-\ from\\:\\ 0\\.011207395691630198\ \(0\)\
\-\ stomach\\:\\ 0\\.011146211862987815\ \(0\)\
\-\ per\\:\\ 0\\.011033464922515255\ \(0\)\
\-\ development\\:\\ 0\\.010978667324954974\ \(0\)\
\-\ pending\\:\\ 0\\.01090715224645942\ \(0\)\
\-\ enhanced\\:\\ 0\\.010786026916672475\ \(0\)\
\-\ suggestive\\:\\ 0\\.010769122271513228\ \(0\)\
\-\ lymphadenopathy\\:\\ 0\\.010718981928243106\ \(0\)\
\-\ levels\\:\\ 0\\.010404871366583962\ \(0\)\
\-\ pelvic\\:\\ 0\\.010345872349750127\ \(0\)\
\-\ family\\:\\ 0\\.010331305147270533\ \(0\)\
\-\ attenuation\\:\\ 0\\.010134575428985364\ \(0\)\
\-\ additional\\:\\ 0\\.010107512372123886\ \(0\)\
\-\ complex\\:\\ 0\\.010094073385292439\ \(0\)\
\-\ 15\\:\\ 0\\.010054119918897875\ \(0\)\
\-\ \\:\\:\\ 0\\.01000243199991739\ \(0\)\
\-\ in\\:\\ 0\\.009944477407439645\ \(0\)\
\-\ cysts\\:\\ 0\\.009874508208942085\ \(0\)\
\-\ subsequent\\:\\ 0\\.009812922412418323\ \(0\)\
\-\ malignancy\\:\\ 0\\.00974067751563869\ \(0\)\
\-\ used\\:\\ 0\\.009670159755008737\ \(0\)\
\-\ within\\:\\ 0\\.009617294444755644\ \(0\)\
\-\ greater\\:\\ 0\\.009468189845635695\ \(0\)\
\-\ occur\\:\\ 0\\.009457364686671205\ \(0\)\
\-\ did\\:\\ 0\\.009101529914433403\ \(0\)\
\-\ or\\:\\ 0\\.008863033176669978\ \(0\)\
\-\ was\\:\\ 0\\.008745818780652096\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.008520921528012057\ \(0\)\
\-\ masses\\:\\ 0\\.008520921528012057\ \(0\)\
\-\ white\\:\\ 0\\.00836018941802955\ \(0\)\
\-\ initial\\:\\ 0\\.0083527496851897\ \(0\)\
\-\ density\\:\\ 0\\.008293897807846487\ \(0\)\
\-\ disease\\:\\ 0\\.008240339476198845\ \(0\)\
\-\ a\\:\\ 0\\.008189376438732179\ \(0\)\
\-\ often\\:\\ 0\\.008042694833391305\ \(0\)\
\-\ between\\:\\ 0\\.007989662348744082\ \(0\)\
\-\ bowel\\:\\ 0\\.007905467648627608\ \(0\)\
\-\ examination\\:\\ 0\\.007836056151842375\ \(0\)\
\-\ 6\\:\\ 0\\.0075283780571530215\ \(0\)\
\-\ ultrasound\\:\\ 0\\.0074782377138829\ \(0\)\
\-\ wall\\:\\ 0\\.007301354336987452\ \(0\)\
\-\ appearance\\:\\ 0\\.007209163943170034\ \(0\)\
\-\ axial\\:\\ 0\\.007194075150642689\ \(0\)\
\-\ likely\\:\\ 0\\.007109999899515211\ \(0\)\
\-\ ct\\:\\ 0\\.00705193895806515\ \(0\)\
\-\ however\\:\\ 0\\.0070187848247701195\ \(0\)\
\-\ an\\:\\ 0\\.006971474125573627\ \(0\)\
\-\ been\\:\\ 0\\.006857802033817083\ \(0\)\
\-\ evidence\\:\\ 0\\.00660897517217368\ \(0\)\
\-\ than\\:\\ 0\\.006604863878814967\ \(0\)\
\-\ for\\:\\ 0\\.006452284501262965\ \(0\)\
\-\ abdominal\\:\\ 0\\.006300646720124234\ \(0\)\
\-\ \\`\\`\\:\\ 0\\.006195088606583531\ \(0\)\
\-\ consistent\\:\\ 0\\.006180820852009449\ \(0\)\
\-\ the\\:\\ 0\\.006117224986886097\ \(0\)\
\-\ \\'\\'\\:\\ 0\\.006075957232985967\ \(0\)\
\-\ \\%\\:\\ 0\\.005880003048218311\ \(0\)\
\-\ other\\:\\ 0\\.005810143211511648\ \(0\)\
\-\ small\\:\\ 0\\.00580700673858737\ \(0\)\
\-\ this\\:\\ 0\\.005670426037251522\ \(0\)\
\-\ lower\\:\\ 0\\.005669209644141187\ \(0\)\
\-\ it\\:\\ 0\\.005666219423401229\ \(0\)\
\-\ contrast\\:\\ 0\\.005642406155775532\ \(0\)\
\-\ left\\:\\ 0\\.005640739051757609\ \(0\)\
\-\ \\'s\\:\\ 0\\.005557659641200722\ \(0\)\
\-\ case\\:\\ 0\\.005514762338841506\ \(0\)\
\-\ have\\:\\ 0\\.005458519405206761\ \(0\)\
\-\ but\\:\\ 0\\.005376115932252323\ \(0\)\
\-\ and\\:\\ 0\\.00531000016909199\ \(0\)\
\-\ after\\:\\ 0\\.005215342780558119\ \(0\)\
\-\ female\\:\\ 0\\.00518218369158653\ \(0\)\
\-\ lesion\\:\\ 0\\.005134381197641459\ \(0\)\
\-\ patient\\:\\ 0\\.005053639710421168\ \(0\)\
\-\ is\\:\\ 0\\.004976024587475448\ \(0\)\
\-\ images\\:\\ 0\\.004835586701915499\ \(0\)\
\-\ has\\:\\ 0\\.0047336282315465425\ \(0\)\
\-\ that\\:\\ 0\\.00435392545297588\ \(0\)\
\-\ normal\\:\\ 0\\.003951659158109443\ \(0\)\
\-\ be\\:\\ 0\\.0038871879744658677\ \(0\)\
\-\ as\\:\\ 0\\.00381291299673784\ \(0\)\
\-\ not\\:\\ 0\\.00364253295499096\ \(0\)\
\-\ year\\:\\ 0\\.0028203695258788046\ \(0\)\
\-\ of\\:\\ 0\\.002749352231220966\ \(0\)\
\-\ old\\:\\ 0\\.002580928014342934\ \(0\)\
\-\ no\\:\\ 0\\.0025381833354094453\ \(0\)\
\-\ \\(\\:\\ 0\\.0021308605493919187\ \(0\)\
\-\ \\)\\:\\ 0\\.0021048309501867407\ \(0\)\
\-\ \\.\\:\\ 0\\.002094367911347863\ \(0\)\
\-\ with\\:\\ 0\\.0020708703732723846\ \(0\)\
\-\ to\\:\\ 0\\.001259787930510284\ \(0\)\
